Pittenger & Anderson Inc. Grows Position in ResMed Inc. $RMD

Pittenger & Anderson Inc. lifted its stake in ResMed Inc. (NYSE:RMD) by 4.4% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 97,952 shares of the medical equipment provider’s stock after purchasing an additional 4,122 shares during the quarter. ResMed comprises about 1.0% of Pittenger & Anderson Inc.’s holdings, making the stock its 24th biggest position. Pittenger & Anderson Inc.’s holdings in ResMed were worth $26,812,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in RMD. Norges Bank bought a new stake in ResMed during the 2nd quarter worth approximately $306,452,000. Vanguard Group Inc. raised its position in shares of ResMed by 1.4% during the 2nd quarter. Vanguard Group Inc. now owns 18,746,925 shares of the medical equipment provider’s stock valued at $4,836,707,000 after purchasing an additional 253,223 shares during the period. Ilex Capital Partners UK LLP purchased a new position in shares of ResMed during the 2nd quarter valued at $39,306,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in ResMed in the 2nd quarter worth $34,443,000. Finally, Swedbank AB increased its stake in ResMed by 25.4% in the 3rd quarter. Swedbank AB now owns 542,711 shares of the medical equipment provider’s stock worth $148,556,000 after buying an additional 109,760 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors.

ResMed Stock Up 0.0%

Shares of NYSE RMD opened at $257.83 on Friday. The company has a current ratio of 2.89, a quick ratio of 2.13 and a debt-to-equity ratio of 0.07. ResMed Inc. has a 12-month low of $199.92 and a 12-month high of $293.81. The firm’s 50-day moving average price is $250.90 and its 200-day moving average price is $263.20. The stock has a market capitalization of $37.63 billion, a price-to-earnings ratio of 26.39, a P/E/G ratio of 1.73 and a beta of 0.88.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. The business had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.40 billion. ResMed had a return on equity of 25.45% and a net margin of 27.35%.The company’s quarterly revenue was up 11.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.43 earnings per share. On average, equities research analysts anticipate that ResMed Inc. will post 9.47 EPS for the current fiscal year.

ResMed Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Investors of record on Thursday, February 12th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Thursday, February 12th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. ResMed’s payout ratio is 24.56%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Royal Bank Of Canada upped their price objective on ResMed from $300.00 to $303.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Stifel Nicolaus cut their price objective on shares of ResMed from $270.00 to $260.00 and set a “hold” rating for the company in a report on Thursday, December 18th. Morgan Stanley set a $305.00 target price on shares of ResMed in a report on Friday, October 31st. KeyCorp raised their target price on shares of ResMed from $298.00 to $299.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Finally, Wells Fargo & Company initiated coverage on shares of ResMed in a research note on Monday, October 13th. They issued an “equal weight” rating and a $280.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, ResMed currently has an average rating of “Moderate Buy” and an average price target of $296.09.

ResMed News Roundup

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q2 results beat expectations — EPS (non?GAAP $2.81) topped estimates and revenue of $1.423B was ~11% year?over?year growth, driven by device and mask demand; investors are pricing in continued top?line momentum. ResMed beats quarterly profit estimates on strong demand for its sleep devices
• Positive Sentiment: Margins and cash flow improved — GAAP gross margin rose ~320 bps to 61.8%, operating cash flow was ~$340M and non?GAAP EPS grew mid?teens, supporting profitability outlook. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Positive Sentiment: Shareholder returns raised — board declared a $0.60 quarterly cash dividend (payable March 19) and the company repurchased $175M of stock in the quarter, boosting capital return credibility. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Neutral Sentiment: Product & regulatory progress — received FDA clearance for an AI?enabled comfort feature (Smart Comfort) that may aid adherence and product differentiation, but commercial impact will be gradual. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Neutral Sentiment: Investor sentiment / analyst context — multiple analysts maintain positive views and price targets remain well above current levels (median ~ $300), which supports upside but also sets expectations. Resmed Inc. Reports 11% Revenue Growth and Strong Margin Improvement in Q2 Fiscal Year 2026
• Negative Sentiment: Costs and one?time items rose — SG&A and R&D grew (~12% yo?y on a constant currency basis) and the company recorded ~$6M of restructuring charges; rising operating expenses could cap margin upside if growth slows. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Negative Sentiment: Insider selling activity noted — recent disclosures show multiple insider sales across senior executives over the past 6 months, which some investors view as a cautionary signal. Resmed Inc. Reports 11% Revenue Growth and Strong Margin Improvement in Q2 Fiscal Year 2026

Insiders Place Their Bets

In related news, CEO Michael J. Farrell sold 4,991 shares of the company’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $248.46, for a total transaction of $1,240,063.86. Following the completion of the sale, the chief executive officer directly owned 466,223 shares in the company, valued at $115,837,766.58. This represents a 1.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Witte Jan De sold 2,055 shares of ResMed stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $255.00, for a total value of $524,025.00. Following the completion of the transaction, the director owned 4,261 shares in the company, valued at $1,086,555. This trade represents a 32.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 21,594 shares of company stock worth $5,403,495 over the last 90 days. Company insiders own 0.65% of the company’s stock.

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.